The increase in price target by Chardan Capital suggests a positive outlook on CRISPR Therapeutics' stock, likely due to strong fundamentals or promising developments within the company. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.